Follow-The-Filings

Security · featured owners

NBIX Neurocrine Biosciences Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 1.9%
  • $954M
  • 1 add 1 reduce

NBIX (Neurocrine Biosciences Inc.) is held in 3 featured 13F books as of 2026 Q2. Nathan Fischel - Dafna Capital Management is the largest tracked holder by portfolio weight (1.9%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 1.9% (Nathan Fischel - Dafna Capital Management) · not free-float ownership

  1. Nathan Fischel reduce 1.9%
  2. Dodge & Cox add 0.49%
  3. Palo Alto Investors 0.42%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Dodge & Cox 2026 Q2 0.49% Add +2.3% 5,584,707 $941M history
Nathan Fischel - Dafna Capital Management 2026 Q2 1.9% Reduce −18.2% 57,769 $10M history
Palo Alto Investors 2026 Q2 0.42% Hold 18,117 $3M history

3 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 4 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
10-Q Filing Doc
8-K/A 9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,5.07 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 14 rows shown

Filed Form Detail Links
4 Period Sep 9, 2026 Filing Doc
4 Period Sep 2, 2026 Filing Doc
4 Period Aug 4, 2026 Filing Doc
4 Period Jul 28, 2026 Filing Doc
4 Period Jul 9, 2026 Filing Doc
4 Period Jul 10, 2026 Filing Doc
4 Period Jul 7, 2026 Filing Doc
4 Period Jun 26, 2026 Filing Doc
4 Period Jun 5, 2026 · 2 forms Filing Doc
4 Period Jun 4, 2026 Filing Doc
4 Period Jun 2, 2026 · 2 forms Filing Doc
4 Period May 29, 2026 Filing Doc
4 Period Jun 1, 2026 Filing Doc
4 Period May 27, 2026 · 10 forms Filing Doc

Updated 4 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.89B $2.36B $2.86B
Gross profit * $1.85B $2.32B $2.81B
Gross margin * 97.9% 98.6% 98.2%
Net income $249.7M $341.3M $478.6M
Net margin * 13.2% 14.5% 16.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.61B $1.72B $2.52B
Total non-current assets * $1.64B $1.99B $2.11B
Total assets $3.25B $3.72B $4.63B
Total current liabilities $654.8M $507.7M $743.4M
Total non-current liabilities * $364.6M $621.3M $635M
Total equity $2.23B $2.59B $3.25B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $389.9M $595.4M $782.7M
Cash from investing -$467.1M -$126.8M -$264.4M
Cash from financing $65.3M -$486.7M -$38.3M
Net change in cash -$11.6M -$18.1M $480M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders